**** PRESS RELEASE from C. Otto Gehrckens ***



High-performance material for the pharmaceuticals industry and biotechnology: EPDM AP 307

The independent seal manufacturer C. Otto Gehrckens has developed the EPDM compound "AP 307" for highly sensitive production processes in the **food** and **pharmaceutical industries**, **biotechnology** and **medical technology**.

Key approvals for applications in these highly demanding sectors have been obtained for this special material in the COG HygienicSeal series. In addition to the safety assessment according to FDA 21 CFR 177.2600, AP 307 has been approved according to USP Chapter 87 and USP Chapter 88 Class VI up to $+121\,^{\circ}$ C. The EPDM compound has also passed the cytotoxicity test (according to ISO 10993-5:2009). The extremely low migration values of this EPDM compound are particularly relevant for applications where there is a risk of contamination with the media being contained by the seal, for example, in cell cultivation or insulin production. What's more, the high-performance material is extremely resistant in contact with CIP and SIP media, and also suitable for applications with aggressive water for injection (WFI). With an operating temperature range of -40 °C to +150 °C, AP 307 has the flexibility to meet special requirements in the production process.

Properties of AP 307

- Special EPDM material for medical technology, the pharmaceutical industry and biotechnology
- Outstanding resistance in CIP/SIP processes
- WFI compatible
- Good resistance in watery media
- Very good resistance to hot water and vapour
- Approved according to USP Chapter 87 and Chapter 88 Class VI up to +121 °C
- FDA approved

Contact:

C. Otto Gehrckens GmbH & Co. KG Gehrstücken 9, 25421 Pinneberg, Germany

Mr Henning Wrage

Phone: +49 (0)4101 5002-0

h.wrage@cog.de

Reprints requested. File copies requested.

Included photos

Produktfoto_AP_307.jpg: High-performance EPDM compound for the food and pharmaceutical industry, biotechnology and medical technology

Image credit: COG

The publication of this photo is approved exclusively for this article (including online). Additional use without consultation is hereby expressly prohibited.